Book contents
- CASE STUDIES Stahl’s Essential Psychopharmacology
- Reviews
- CASE STUDIES: Stahl’s Essential Psychopharmacology
- Copyright page
- Contents
- Introduction
- List of icons
- Abbreviations
- Case 1: The salutatorian who couldn’t speak: selective serotonin reuptake inhibitor (SSRI)-refractory anxiety in an adolescent
- Case 2: From anxious to activated: selective serotonin reuptake inhibitor (SSRI)-related activation
- Case 3: The girl who couldn’t sleep: posttraumatic stress disorder (PTSD) in a young girl
- Case 4: Depressed and still depressed: major depressive disorder (MDD) in an adolescent
- Case 5: A 13-year-old adolescent who feels “amazing”: selective serotonin reuptake inhibitor (SSRI)-induced mania in an adolescent
- Case 6: Counting on a cure: obsessive compulsive disorder (OCD) in an adolescent
- Case 7: Struggles in the second grade: attention-deficit hyperactivity disorder (ADHD) in a child
- Case 8: From prodrome to psychosis: early-onset schizophrenia
- Case 9: Too much, too little, or just right? Lithium dosing in an adolescent
- Case 10: Tic, tic, tic: motor and vocal tics in a boy
- Case 11: How slow can you go? Selective serotonin reuptake inhibitor (SSRI) withdrawal and discontinuation in an adolescent
- Case 12: The adolescent who doesn’t eat: anorexia nervosa in an adolescent
- Case 13: High or higher antidepressant concentrations? Cannabis-related drug interactions in an adolescent
- Case 14: The boy whose bed was always wet: nocturnal enuresis in a child
- Case 15: Counting sheep and counting treatment trials: insomnia disorder in an adolescent
- Case 16: Second-generation antipsychotics/mixed dopamine–serotonin receptor agonists (SGAs), side effects, and the autism spectrum: SGA-related side effects in a boy with autism spectrum disorder (ASD)
- Case 17: The “standard treatment” is earning a “D”: treatment-resistant schizophrenia
- Case 18: Symptoms, side effects, or both? Selective serotonin reuptake inhibitor (SSRI) tolerability and physical symptoms in an anxious adolescent
- Book part
- Case Studies Index
- Drugs Index
- References
Case 17: The “standard treatment” is earning a “D”: treatment-resistant schizophrenia
Published online by Cambridge University Press: 09 February 2024
Book contents
- CASE STUDIES Stahl’s Essential Psychopharmacology
- Reviews
- CASE STUDIES: Stahl’s Essential Psychopharmacology
- Copyright page
- Contents
- Introduction
- List of icons
- Abbreviations
- Case 1: The salutatorian who couldn’t speak: selective serotonin reuptake inhibitor (SSRI)-refractory anxiety in an adolescent
- Case 2: From anxious to activated: selective serotonin reuptake inhibitor (SSRI)-related activation
- Case 3: The girl who couldn’t sleep: posttraumatic stress disorder (PTSD) in a young girl
- Case 4: Depressed and still depressed: major depressive disorder (MDD) in an adolescent
- Case 5: A 13-year-old adolescent who feels “amazing”: selective serotonin reuptake inhibitor (SSRI)-induced mania in an adolescent
- Case 6: Counting on a cure: obsessive compulsive disorder (OCD) in an adolescent
- Case 7: Struggles in the second grade: attention-deficit hyperactivity disorder (ADHD) in a child
- Case 8: From prodrome to psychosis: early-onset schizophrenia
- Case 9: Too much, too little, or just right? Lithium dosing in an adolescent
- Case 10: Tic, tic, tic: motor and vocal tics in a boy
- Case 11: How slow can you go? Selective serotonin reuptake inhibitor (SSRI) withdrawal and discontinuation in an adolescent
- Case 12: The adolescent who doesn’t eat: anorexia nervosa in an adolescent
- Case 13: High or higher antidepressant concentrations? Cannabis-related drug interactions in an adolescent
- Case 14: The boy whose bed was always wet: nocturnal enuresis in a child
- Case 15: Counting sheep and counting treatment trials: insomnia disorder in an adolescent
- Case 16: Second-generation antipsychotics/mixed dopamine–serotonin receptor agonists (SGAs), side effects, and the autism spectrum: SGA-related side effects in a boy with autism spectrum disorder (ASD)
- Case 17: The “standard treatment” is earning a “D”: treatment-resistant schizophrenia
- Case 18: Symptoms, side effects, or both? Selective serotonin reuptake inhibitor (SSRI) tolerability and physical symptoms in an anxious adolescent
- Book part
- Case Studies Index
- Drugs Index
- References
Summary
In addition to D2 antagonism, clozapine’s effect at which of the following receptors may contribute to its antipsychotic efficacy?
- Type
- Chapter
- Information
- Case Studies: Stahl's Essential PsychopharmacologyChildren and Adolescents, pp. 279 - 300Publisher: Cambridge University PressPrint publication year: 2023
References
Brouwers, E. E. M., Söhne, M., Kuipers, S., et al. Ciprofloxacin strongly inhibits clozapine metabolism: two case reports. Clin Drug Invest 2009; 29(1): 59–63. https://doi.org/10.2165/0044011-200929010-00006Google Scholar
de Leon, J. Benztropine equivalents for antimuscarinic medication. Am J Psychiatry 2005; 162(3): 627. https://doi.org/10.1176/appi.ajp.162.3.627Google Scholar
Espnes, K. A., Heimdal, K. O., Spigset, O. A puzzling case of increased serum clozapine levels in a patient with inflammation and infection. Ther Drug Monitor 2012; 34(5): 489–92. https://doi.org/10.1097/FTD.0b013e3182666c62Google Scholar
Haslemo, T., Eikeseth, P. H., Tanum, L., Molden, E., Refsum, H. The effect of variable cigarette consumption on the interaction with clozapine and olanzapine. Eur J Clin Pharmacol 2006; 62(12): 1049–53. https://doi.org/10.1007/s00228-006-0209-9CrossRefGoogle ScholarPubMed
Kapur, S., Remington, G., Zipursky, R. B., Wilson, A. A., Houle, S. The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sci 1995; 57(10): PL103–07. https://doi.org/10.1016/0024-3205(95)02037-JGoogle Scholar
Kapur, S., Zipursky, R., Jones, C., et al. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 2000; 57(6): 553–59. https://doi.org/10.1001/archpsyc.57.6.553Google Scholar
Lopez, L. V., Shaikh, A., Merson, J., Accuracy of clinician assessments of medication status in the emergency setting: a comparison of clinician assessment of antipsychotic usage and plasma level determination. J Clin Psychopharmacol 2017; 37(3): 310–14. https://doi.org/10.1097/JCP.0000000000000697Google Scholar
MacEwan, J. P., Forma, F. M., Shafrin, J., et al. Patterns of adherence to oral atypical antipsychotics among patients diagnosed with schizophrenia. J Manag Care Specialty Pharm 2016; 22(11): 1349–61. https://doi.org/10.18553/jmcp.2016.22.11.1349Google Scholar
Meyer, J. M., Proctor, G., Cummings, M. A., Dardashti, L. J., Stahl, S. M. Ciprofloxacin and clozapine: a potentially fatal but underappreciated interaction. Case Rep Psychiatry 2016; 2016: 5606098. https://doi.org/10.1155/2016/5606098Google Scholar
Meyer, J. M., Stahl, S. M. The Clozapine Handbook. Cambridge, UK: Cambridge University Press, 2019. https://doi.org/10.1017/9781108553575Google Scholar
Meyer, J. M., Stahl, S. M. The Clinical Use of Antipsychotic Plasma Levels. Cambridge, UK: Cambridge University Press, 2021. https://doi.org/10.1017/9781009002103CrossRefGoogle Scholar
Nielsen, J., Meyer, J. M. Risk factors for ileus in patients with schizophrenia. Schizophrenia Bull 2012; 38(3): 592–98. https://doi.org/10.1093/schbul/sbq137Google Scholar
Sambhi, R. S., Puri, R., Jones, G. Interaction of clozapine and ciprofloxacin: a case report. Eur J Clin Pharmacol 2007; 63(9): 895–96. https://doi.org/10.1007/s00228-007-0313-5Google Scholar
Velligan, D. I., Lam, Y. W. F., Glahn, D. C., et al. Defining and assessing adherence to oral antipsychotics: a review of the literature. Schizophrenia Bull 2006; 32(4): 724–42. https://doi.org/10.1093/schbul/sbj075Google Scholar
Yaegashi, H., Kirino, S., Remington, G., Misawa, F., Takeuchi, H. Adherence to oral antipsychotics measured by electronic adherence monitoring in schizophrenia: a systematic review and meta-analysis. CNS Drugs 2020; 34(6): 579–98. https://doi.org/10.1007/s40263-020-00713-9Google Scholar
Komaryk, A., Elbe, D., Burgess, L. Retrospective review of clozapine use in children and adolescents. J Can Acad Child Adolesc Psychiatry 2021; 30(1): 36–48Google Scholar